ATAI Life Sciences B.V.* ATAI 深 沪
已收盘 12-19 16:00:00 美东时间
3.975
+0.065
+1.66%
华盛通- 最 高4.63
- 今 开3.93
- 成交量 427.24万股
- 最 低 3.60
- 昨 收 3.91
- 总市值 6.40亿
- 52周最高 6.725
- 市盈率 静 --
- 换手率 2.65%
- 52周最低 1.15
- 委 比 -25.23%
- 总股本 1.61亿
- 历史最高 22.91
- 量 比 2.22
- 振 幅 26.34%
- 历史最低 1.00
- 每 手 1
- 风险率 1.52%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies
atai Life Sciences and Beckley Psytech to merge, forming atai Beckley, to focus on rapid-acting psychedelic therapies for mental health. The merger includes BPL-003, a potential breakthrough for treatment-resistant depression, with Phase 2b data expected in mid-2025. The transaction is set to close in 2025H2 alongside a $30M private placement.
06-02 10:00
atai Life Sciences to Participate in Upcoming Investor Conferences
atai Life Sciences announced its management team will participate in two investor conferences in June. The first is a Fireside Chat at the Jefferies Global Healthcare Conference on June 5 in New York, and the second is a pre-recorded Fireside Chat at the H.C. Wainwright Neuro Perspectives Conference on June 17, available virtually. Webcasts will be accessible via the company's website under Events, with replays following the live events.
05-29 12:30
MDMA Therapy For PTSD Faces FDA Delay: Are There Other Ways Forward?
The U.S. Food and Drug Administration (FDA) has issued a complete response lett...
2024-09-13 08:28
Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration
The global psychedelic drugs market is projected to grow by USD 1.37 billion by 2028, driven by mental health needs and AI advancements in drug development.
2024-09-06 00:53
